Tumor　acidic　environment-activated　combination　therapy　holds　great　promise　to　significantly　decrease　side　effects,　circumvent　multiple　drug　resistance,　and　improve　therapeutic　outcomes　for　cancer　treatment.　Herein,　Sorafenib/ZnPc(PS)(4)@Fe-III-TA　nanoparticles　(SPFT)　are　designed　with　acid-environment　turned-on　fluorescence　to　report　the　activation　of　triple　therapy　including　photodynamic,　chemodynamic,　and　chemotherapy　on　hepatocellular　carcinoma.　The　SPFT　are　composed　of　SP　cores　formulated　via　self-assembly　of　sorafenib　and　ZnPc(PS)(4),　with　high　drug　loading　efficiency,　and　Fe-III-TA　shells　containing　FeCl3　and　tannic　acid.　Importantly,　the　nanoparticles　suppress　reactive　oxygen　species　(ROS)　generation　of　ZnPc(PS)(4)　due　to　their　formation　in　nanoparticles,　while　assisting　simultaneous　uptake　of　the　uploaded　drugs　in　cancer　cells.　The　tumor　acidic　environment　initiates　Fe-III-TA　decomposition　and　accelerates　a　chemodynamic　reaction　between　Fe(II　)and　H2O2　to　generate　toxic　center　dot　OH.　Then,　the　SP　core　is　decomposed　to　separate　ZnPc(PS)(4)　and　sorafenib,　which　leads　to　fluorescence　turning-on　of　ZnPc(PS)(4),　expedited　photodynamic　reactions,　and　burst　release　of　sorafenib.　Notably,　SPFT　shows　low　dark　cytotoxicity　to　normal　cells　but　exerts　high　potency　on　hepatocellular　carcinoma　cells　under　near-infrared　light　irradiation,　which　is　much　more　potent　than　either　sorafenib　or　ZnPc(PS)(4)　alone.　This　research　offers　a　facile　nanomedicine　design　strategy　for　cancer　therapy.